about
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogueAnthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicityDefective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms.An introduction to the metabolic determinants of anthracycline cardiotoxicity.Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.The concomitant management of cancer therapy and cardiac therapy.Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin.4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.Pharmacological foundations of cardio-oncology.Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship.Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metaboliteDefective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapiesDoxorubicin degradation in cardiomyocytesCardiotoxicity of antitumor drugsPaclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapiesPharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicinPharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicinMatters of the heart: the case of TNFalpha-targeting drugsAnthracycline cardiotoxicityPharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosisAnthracycline cardiotoxicityEfficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia
P50
Q28363755-545339E0-85F3-4A3B-8647-531C5F454D32Q29614981-5F39B844-FC3B-4591-898A-10E9DE427CE7Q33232092-342B3C15-175E-44A7-B6AE-5B81D9B86F85Q35708054-BA334E3A-FC9D-465F-AA27-9E7D9697F169Q36891719-E8A51FD2-AB33-4112-BF12-5AA2D68410B3Q37642751-9AC6DFAA-A82C-4D57-AB44-D24657F8F304Q37871666-B2CFB5C3-488E-4715-89E2-FE2D82B95F58Q38321789-6A073B26-D1D9-43A5-BD38-8895CFCD7646Q38977933-A5AE7545-3DC2-4A8A-8A94-89BDED27F08AQ38998367-985125F8-AD34-48C3-8C82-1704A9E4AF30Q43906042-1D49F84A-E286-403D-B012-C68E81599190Q44666436-3C44F407-2C5C-4889-A480-BCAB84815882Q46035361-8C3986D9-7609-4D83-8D5E-5D3784229641Q47617394-F9CD6D2E-F825-4414-9E89-D1A2716939C3Q50282791-13DFA5E8-D75B-44E6-8AA9-DC75243CCC6FQ73313569-02D99ACB-F87F-4CB9-B251-172273E1343AQ79393786-46BDAE96-A6E4-45C7-9C5C-558C0F96FDABQ80236768-97C5425B-B6C0-42B4-8A84-09F7A173BA17Q80982459-55D40053-31EA-4B0A-9F5F-5E2E7E3A1CE4Q83154015-B977AE9E-9115-4EBA-9F36-E0A9D4A1424FQ83455929-BA9DC045-384F-415A-9D81-F0995FE1AD19Q83455932-E75AB217-7872-413A-8650-9DCB26DB8869Q84028261-5B5C5943-677F-414A-A9A8-40A053E2ADF2Q84255313-B50DED18-E2D2-4BAE-BAE4-8F01F06E2DA0Q84966959-9A536603-8884-4873-9DB1-CA2FBD08CA88Q86633330-B144006F-F1F2-4B6D-B8DC-1F69414EAB16Q92330395-7F2CF259-5ED7-4CE6-8694-442A0D7C242B
P50
description
researcher ORCID ID = 0000-0002-7755-818X
@en
wetenschapper
@nl
name
Pierantonio Menna
@ast
Pierantonio Menna
@en
Pierantonio Menna
@es
Pierantonio Menna
@nl
type
label
Pierantonio Menna
@ast
Pierantonio Menna
@en
Pierantonio Menna
@es
Pierantonio Menna
@nl
prefLabel
Pierantonio Menna
@ast
Pierantonio Menna
@en
Pierantonio Menna
@es
Pierantonio Menna
@nl
P31
P496
0000-0002-7755-818X